巨细胞关节炎:了解病变的进展和临床实践的影响
Marino Paroli1, Rosalba Caccavale1, Daniele Accapezzato1
1Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy.
Cells
|February 9, 2024
概括
巨细胞动脉炎 (GCA) 是一种影响老年人的炎症状况. 研究探索其分子和细胞机制,以找到新的诊断生物标志物和超越葡萄皮质激素的向治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 病理学 病理学 病理学
背景情况:
- 巨细胞动脉炎 (GCA) 是一种非传染性粒状血管炎,主要影响50岁以上的人.
- 它呈现于 (关动脉炎) 和外形式,影响大血管,如大动脉.
- 遗传倾向和表观遗传因素有助于GCA的发展.
研究的目的:
- 审查对GCA分子和细胞病原学的新见解.
- 讨论对开发新型诊断生物标志物的影响.
- 探索可能取代当前葡萄糖皮质激素治疗的向疗法.
主要方法:
- 关于GCA病变的当前文献的综述.
- 对参与颗粒瘤形成和血管改造的分子和细胞机制的分析.
- 讨论新出现的诊断和治疗策略.
主要成果:
- 天生和适应性免疫细胞在形成粒瘤和动脉三级淋巴体器官方面至关重要.
- 血管壁细胞,包括VSMC和内皮细胞,积极参与血管重塑,导致狭窄和缺血.
- 新的理解指向了潜在的生物标志物和有针对性的药物开发.
结论:
- 阐明GCA复杂的致病性是推动诊断和治疗的关键.
- 向治疗有望改善患者的治疗结果,并减少对葡萄糖皮质激素的依赖.
- 对分子和细胞通路的进一步研究对于开发有效的治疗方法至关重要.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
COPD: Pathogenesis and Clinical Features
273
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
273
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166


